BRPI0409440A - composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença - Google Patents

composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença

Info

Publication number
BRPI0409440A
BRPI0409440A BRPI0409440-9A BRPI0409440A BRPI0409440A BR PI0409440 A BRPI0409440 A BR PI0409440A BR PI0409440 A BRPI0409440 A BR PI0409440A BR PI0409440 A BRPI0409440 A BR PI0409440A
Authority
BR
Brazil
Prior art keywords
patient
aromatic alcohol
pharmaceutical composition
active macromolecular
macromolecular principle
Prior art date
Application number
BRPI0409440-9A
Other languages
English (en)
Inventor
Roger R C New
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Publication of BRPI0409440A publication Critical patent/BRPI0409440A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, USO DE UM áLCOOL AROMáTICO, E, MéTODOS PARA INTENSIFICAR A ABSORçãO DE UM PRINCìPIO MACROMOLECULAR ATIVO EM UM PACIENTE E PARA TRATAR UM PACIENTE QUE ESTEJA SOFRENDO DE UMA CONDIçãO OU DOENçA". A invenção provê uma composição farmacêutica compreendendo uma mistura de (a) um princípio macromolecular ativo, e (b) um intensificador de absorção de álcool aromático escolhido dentre hidroxitolueno butilado, hidroxianisol butilado e seus análogos e derivados, em que o intensificador de absorção de álcool aromático está presente em uma quantidade em peso maior ou igual àquela do princípio macromolecular ativo e adicionalmente compreende uma composição farmacêutica compreendendo uma mistura de (a) um princípio macromolecular ativo, (b) um intensificador de absorção de álcool aromático escolhido dentre galato de propila, hidroxitolueno butilado, hidroxianisol butilado e seus análogos e derivados, em que o intensificador de absorção de álcool aromático está presente em uma quantidade em peso maior ou igual àquela do princípio macromolecular ativo, e (c) um auxiliar de solubilização capaz de aumentar a solubilidade do intensificador de absorção de álcool aromático em meios aquosos.
BRPI0409440-9A 2003-04-15 2004-04-15 composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença BRPI0409440A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308732.7A GB0308732D0 (en) 2003-04-15 2003-04-15 Absorption enhancers
PCT/GB2004/001650 WO2004091584A1 (en) 2003-04-15 2004-04-15 Absorption enhancers such as e.g. bht, bha or propyl gallate

Publications (1)

Publication Number Publication Date
BRPI0409440A true BRPI0409440A (pt) 2006-04-18

Family

ID=9956846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409440-9A BRPI0409440A (pt) 2003-04-15 2004-04-15 composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença

Country Status (13)

Country Link
US (3) US7651995B2 (pt)
EP (1) EP1620073A1 (pt)
JP (1) JP5016919B2 (pt)
KR (1) KR101135822B1 (pt)
CN (1) CN1805733A (pt)
AU (1) AU2004229216B2 (pt)
BR (1) BRPI0409440A (pt)
CA (1) CA2522098C (pt)
GB (1) GB0308732D0 (pt)
NZ (1) NZ543171A (pt)
RU (1) RU2341281C2 (pt)
WO (1) WO2004091584A1 (pt)
ZA (1) ZA200508343B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
US7748144B2 (en) * 2005-10-26 2010-07-06 Pamela Denfeld Vehicle shaped footwear
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
CN101361881B (zh) * 2008-09-09 2011-02-16 上海沈李科工贸有限公司 蛋白药物溶菌酶肠道吸收促进剂的制备方法
CA2755068C (en) 2009-03-12 2018-11-06 Keybioscience Ag Treatment of diabetes and metabolic syndrome
CN101947315B (zh) * 2010-09-03 2013-01-30 上海沈李科工贸有限公司 中药杏仁促进溶菌酶海藻酸钠微球肠道吸收的应用
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA2733836A1 (en) * 2011-03-09 2012-09-09 Coorga International Holding Ltd. Oral dietary supplementation for addressing of human canities
US9006172B2 (en) 2011-11-02 2015-04-14 Keybioscience Ag Peptide analogs for treating diseases and disorders
EP3357540A1 (en) 2011-11-02 2018-08-08 KeyBioscience AG Combination of calcitonin mimetic and insulin sensitizer
JP5877935B2 (ja) 2012-10-17 2016-03-08 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティＭｅｔｈｙｌａｔｉｏｎ Ｓｃｉｅｎｃｅｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓｒｌ Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
CN105722854B (zh) 2013-11-14 2020-08-04 关键生物科学有限公司 用于治疗疾病和病症的降钙素模拟物
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
CN118634202A (zh) 2016-08-05 2024-09-13 帕克治疗公司 室温稳定的口服降钙素制剂
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
WO2020161771A1 (ja) * 2019-02-04 2020-08-13 マルホ株式会社 皮膚用組成物
KR20210026408A (ko) 2019-08-30 2021-03-10 좋은영농조합법인 항산화 활성을 갖는 비파잎 추출물 및 이의 제조방법
WO2024238657A2 (en) 2023-05-15 2024-11-21 Bonafide Health, Llc Sleep-improving compositions and methods of use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US618066A (en) * 1899-01-24 Fence-post
GB354184A (en) 1929-04-30 1931-07-29 Pharmagans Pharmaceutisches In An improved process for the production of hormone preparations
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
JPS5257313A (en) 1975-11-07 1977-05-11 Yamanouchi Pharmaceut Co Ltd Manufacture of micellar insuline emulsion preparations
JPS56138168A (en) 1980-03-31 1981-10-28 Teijin Ltd Movel active vitamin d3 derivative composition
FR2500097B1 (fr) * 1981-02-17 1986-04-04 Commerce Internal Echanges Tec Support amortisseur antivibratile, antichocs
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1251685B (it) * 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
JPH05246846A (ja) 1992-03-03 1993-09-24 Taiyo Kagaku Co Ltd 蛋白質の消化促進組成物
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
CA2224227A1 (en) 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO1997021448A1 (en) 1995-12-13 1997-06-19 Dullatur Limited A calcitonin preparation
CA2198966C (en) * 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
US6180666B1 (en) * 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE60001667T2 (de) 2000-03-31 2004-01-29 Council Scient Ind Res Getreidenahrungsmittel mit hohem nährwert
JP2003532691A (ja) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
ES2292496T3 (es) * 2000-09-18 2008-03-16 Rpg Life Sciences Limited Formulacion autoemulsionable con elevada actividad inmunosupresora y bioabsorbente.
GB2368792A (en) * 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6951655B2 (en) * 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
CA2471081A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
GB0206792D0 (en) * 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules

Also Published As

Publication number Publication date
US20150093419A1 (en) 2015-04-02
KR101135822B1 (ko) 2012-04-16
NZ543171A (en) 2009-03-31
KR20060023114A (ko) 2006-03-13
CN1805733A (zh) 2006-07-19
US20100056425A1 (en) 2010-03-04
EP1620073A1 (en) 2006-02-01
US20060223740A1 (en) 2006-10-05
RU2005135433A (ru) 2006-06-10
AU2004229216B2 (en) 2010-04-01
CA2522098C (en) 2013-11-12
GB0308732D0 (en) 2003-05-21
CA2522098A1 (en) 2004-10-28
WO2004091584A1 (en) 2004-10-28
ZA200508343B (en) 2007-12-27
RU2341281C2 (ru) 2008-12-20
AU2004229216A1 (en) 2004-10-28
JP5016919B2 (ja) 2012-09-05
US7651995B2 (en) 2010-01-26
JP2006523662A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
BRPI0409440A (pt) composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença
BR112022024943A2 (pt) Composição oral efervescente compreendendo um ingrediente ativo
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR0308613A (pt) Combinação de compostos orgânicos
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
WO2021202245A1 (en) Viral treatment regimens
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
CL2004000954A1 (es) Composicion parasiticida en animales que contiene flumetrina y mkg 264 (n-octil biciclohepteno dicarboxamida) en una relacion en peso de al menos 1:20, eventualmente otros principios activos vehiculos y coadyuvantes, y uso de la composicion para prep
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
BRPI0414644A (pt) composto, composições farmacêuticas, e, uso de um composto
BRPI0410840A (pt) derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
US12005066B2 (en) Cobinamide compounds as a cyanide, sulfide, or methane-thiol antidote
PE20061245A1 (es) Composiciones para la transmision transmucosa oral de la metformina
ATE444302T1 (de) Neue cholest-4-en-3-onoximderivate, pharmazeutische zusammensetzungen, die diese enthalten, und herstellungsverfahren
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi
DK0853476T3 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AXCESS LIMITED (GB)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090000996/RJ DE 06/01/2009.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]